XERS
XERS clinical trials: Xeris Biopharma Holdings, Inc.
Every trial on ClinicalTrials.gov where Xeris Biopharma Holdings, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 19
- Trials linked
- 15
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
XERS on the catalyst calendar · XERS registry changes
- Primary completion Apr 2, 2020ActualPhase 2NCT03841526Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1DXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2024ActualPhase 2NCT05823012Study of XP-8121 For the Treatment of Adult Subjects With HypothyroidismXeris Pharmaceuticals · HypothyroidismCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2020ActualPhase 2NCT04074317Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1DXeris Pharmaceuticals · Diabetes Mellitus, Type 1CompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2019ActualPhase 2NCT03490942Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory ResponsesXeris Pharmaceuticals · Hypoglycemia UnawarenessTerminatedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2020ActualPhase 2NCT03770637Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric SurgeryXeris Pharmaceuticals · Hyperinsulinemic HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2019ActualPhase 3NCT03738865G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 DiabetesXeris Pharmaceuticals · Insulin HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2018ActualPhase 3NCT03439072G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 DiabetesXeris Pharmaceuticals · Insulin HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2018ActualPhase 2NCT02937558CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital HyperinsulinismXeris Pharmaceuticals · Congenital HyperinsulinismCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2017ActualPhase 3NCT03091673Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D PatientsXeris Pharmaceuticals · Diabetes Mellitus, Type 1CompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2017ActualPhase 2NCT02733588Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery PatientsXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2017ActualPhase 3NCT02656069Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 DiabeticsXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2NCT02081014Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 DiabetesXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 2NCT02081001PK/PD Study With G-Pump (Glucagon Infusion) in T1DM PatientsXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 2NCT02423980G-Pen™ for Hypoglycemia Rescue in T1D PatientsXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 2NCT01972152Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe HypoglycemiaXeris Pharmaceuticals · HypoglycemiaCompletedXERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2018ActualPhase 1/Phase 2NCT03255629Closed-Loop Glucagon Pump for Treatment of Post-Bariatric HypoglycemiaJoslin Diabetes Center · Post-bariatric HypoglycemiaCompletedXERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2019ActualPhase 1NCT03424044Three Way Crossover Closed Loop Study With Xeris GlucagonOregon Health and Science University · Type1diabetesCompletedXERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2017ActualPhase 2NCT02660242The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 DiabetesJaeb Center for Health Research · Diabetes Mellitus, Type 1CompletedXERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2016ActualPhase 2NCT02411578Mini-Dose Glucagon to Treat Non-Severe HypoglycemiaJaeb Center for Health Research · Diabetes Mellitus, Type 1CompletedXERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner